Premium
Axillary lymph node dissection for intraductal breast carcinoma‐is it indicated?
Author(s) -
Silverstein Melvin J.,
Rosser Robert J.,
Gierson Eugene D.,
Waisman James R.,
Gamagami Parvis,
Hoffman Robert S.,
Fingerhut Aaron G.,
Lewinsky Bernard S.,
Colburn William,
Handel Neal
Publication year - 1987
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19870515)59:10<1819::aid-cncr2820591023>3.0.co;2-v
Subject(s) - medicine , axillary lymph node dissection , breast carcinoma , lymph node , carcinoma , lymph , axillary lymph nodes , axillary dissection , mastectomy , breast cancer , radiation therapy , dissection (medical) , axilla , radiology , metastasis , surgery , cancer , sentinel lymph node , pathology
One hundred patients with intraductal breast carcinoma (DCIS) were treated with either mastectomy (49 patients) or radiation therapy (51 patients). All patients underwent axillary lymph node dissection (average number of nodes removed, 16) as part of their treatment. No patient had any positive axillary lymph nodes. There has been one recurrence in each treatment group (median follow‐up, 27 months) and no deaths. Intraductal breast carcinoma has little potential for metastasis to axillary lymph nodes.